2024
Factors Associated With Surgical Management in Gallbladder Cancer—A Surveillance, Epidemiology, and End Results Medicare–Based Study
Romatoski K, Chung S, Sawhney V, Papageorge M, de Geus S, Ng S, Kenzik K, Tseng J, Sachs T. Factors Associated With Surgical Management in Gallbladder Cancer—A Surveillance, Epidemiology, and End Results Medicare–Based Study. Journal Of Surgical Research 2024, 304: 9-18. PMID: 39481161, DOI: 10.1016/j.jss.2024.09.084.Peer-Reviewed Original ResearchGallbladder cancer patientsGallbladder cancerOncologic resectionStage T1bComplete resectionOverall survivalSurgical oncologistsGeneral surgeonsChi-square and Wilcoxon rank-sum testsOverall survival outcomesNonacademic hospitalsWilcoxon rank sum testRank sum testResection rateSurgical managementSurvival outcomesImproved survivalBaseline characteristicsResectionSEER-MedicarePatient factorsAcademic centersPatientsCCI patientsFrail statusPerioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.
Cohen D, Goldberg J, Leichman L, Hochman T, Newman E, Du K, Megibow A, Oberstein P, Al-Rajabi R, Scott A, Bekaii-Saab T, Messersmith W, Weekes C. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial. Journal Of Clinical Oncology 2024, 42: 4175-4175. DOI: 10.1200/jco.2024.42.16_suppl.4175.Peer-Reviewed Original ResearchR0 resection rateBR-PDACR0 resectionNeoadjuvant therapyR-PDACResection ratePancreatic adenocarcinomaOverall survivalResected tumorAdverse eventsImproved R0 resection ratesNon-hematological adverse eventsBorderline resectable pancreatic adenocarcinomaPhase 2 clinical trialBorderline resectable tumorsBR-PDAC patientsCentral radiology reviewLocalized pancreatic adenocarcinomaMulticenter open-labelCycles of gemcitabineResectable pancreatic adenocarcinomaStereotactic radiation therapyComplete surgical resectionHematologic AENab-paclitaxel
2023
Clinical and oncological outcomes of pelvic exenteration surgery for anal squamous cell carcinoma
Quyn A, Murthy S, Gould L, Said H, Tiernan J, Sagar P, Antoniou A, Jenkins I, Burns E. Clinical and oncological outcomes of pelvic exenteration surgery for anal squamous cell carcinoma. Colorectal Disease 2023, 25: 2131-2138. PMID: 37753947, DOI: 10.1111/codi.16736.Peer-Reviewed Original ResearchConceptsAnal squamous cell carcinomaSquamous cell carcinomaDisease-free survivalR0 resectionR1/R2 resectionPelvic exenterationOverall survivalRecurrent diseaseCell carcinomaTreated with pelvic exenterationComplete R0 resectionPelvic exenteration surgeryAnal cancer incidenceR0 resection rateMedian follow-upPoorer overall survivalR1/2 resectionR1 resectionR2 resectionExenteration surgeryOncological outcomesResection ratePrimary endpointRetrospective reviewTreatment modalitiesAssessment of a collaborative treatment model for trimodal management of esophageal cancer
Udelsman B, Ermer T, Ely S, Canavan M, Zhan P, Boffa D, Blasberg J. Assessment of a collaborative treatment model for trimodal management of esophageal cancer. Journal Of Thoracic Disease 2023, 15: 4668-4680. PMID: 37868899, PMCID: PMC10586936, DOI: 10.21037/jtd-23-346.Peer-Reviewed Original ResearchPathologic complete responseNational Cancer DatabaseGy of radiationEsophageal cancerCollaborative treatmentCollaborative treatment modelMultiagent chemotherapySingle institutionRate of pCRPatient travel burdenR0 resection rateTreatment modelTrimodality therapyTrimodality treatmentNeoadjuvant chemoradiotherapyNeoadjuvant therapyR0 resectionResection rateComplete responseMultivariable analysisTumor characteristicsCancer DatabaseMedian travel distancePatientsCollaborative CohortPhase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G, Group O. Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine 2023, 12: 12986-12995. PMID: 37132281, PMCID: PMC10315770, DOI: 10.1002/cam4.5971.Peer-Reviewed Original ResearchConceptsNab-paclitaxelNeoadjuvant treatmentDefinitive resectionResection rateAdverse eventsPancreatic adenocarcinomaOpen-label phase 2 trialNode-positive pancreatic cancerLong-course chemoradiationNab-paclitaxel 125Neoadjuvant treatment strategiesOperable pancreatic adenocarcinomaRadiographic response rateCommon adverse eventsR0 resection ratePhase 2 studyPhase 2 trialProgression-free survivalProspective interventional trialNegative surgical marginsTreatment completion ratesPancreatic ductal adenocarcinomaIntensity-modulated radiationGemcitabine 1000Positive nodes
2020
Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review
Cheong C, Nistala K, Ng C, Syn N, Chang H, Sundar R, Yang S, Chong C. Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review. Journal Of Gastrointestinal Oncology 2020, 11: 847-857. PMID: 33209481, PMCID: PMC7657836, DOI: 10.21037/jgo-20-220.Peer-Reviewed Original ResearchLocally advanced colon cancerAdvanced colon cancerR0 resection rateDisease-free survivalNeoadjuvant chemotherapyColon cancerNeoadjuvant therapyRandomized controlled trialsOverall survivalResection rateAdjuvant chemotherapyChina Knowledge Resource Integrated DatabaseSurvival benefit of neoadjuvant chemotherapyBenefit of neoadjuvant chemotherapyRisk of peri-operative complicationsObservational studyObservational study of patientsAdverse effects of chemotherapyPeri-operative complicationsPotential survival benefitMeta-analysisEffects of chemotherapyStudy of patientsFOxTROT trialUpfront operationPredictors of 30‐ and 90‐Day Readmissions After Complex Abdominal Wall Reconstruction With Biological Mesh: A Longitudinal Study of 232 Patients
Gogna S, Latifi R, Choi J, Con J, Prabhakaran K, Smiley A, Anderson P. Predictors of 30‐ and 90‐Day Readmissions After Complex Abdominal Wall Reconstruction With Biological Mesh: A Longitudinal Study of 232 Patients. World Journal Of Surgery 2020, 44: 3720-3728. PMID: 32734453, DOI: 10.1007/s00268-020-05714-9.Peer-Reviewed Original ResearchConceptsComplex abdominal wall reconstructionAbdominal wall reconstructionReadmission groupReadmission ratesHigher surgical site infectionPresence of enterocutaneous fistulaBiologic meshWall reconstructionAssociated with 30-dayConcomitant pelvic surgeryClavien-Dindo complicationsPresence of ascitesAssociated with 90-day readmissionIntestinal resection rateSurgical site infectionIncreased patient morbiditySurgical site occurrencesMultivariate logistic regression modelFischer's exact testPlacement of meshAcellular porcine dermisDatabase patientsPelvic surgeryResection rateASA scoreA Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas 2020, 49: 904-911. PMID: 32658074, DOI: 10.1097/mpa.0000000000001592.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaLA PDACUnresectable pancreatic ductal adenocarcinomaInduction FOLFIRINOXConsolidative radiotherapyOverall survivalAdvanced unresectable pancreatic ductal adenocarcinomaSingle-center retrospective reviewMeaningful survival benefitMedian overall survivalUnresectable pancreatic cancerR0 resection rateKaplan-Meier methodSingle institution experienceBenefits of surgeryLog-rank testConsolidative radiationDefinitive radiationLA patientsPreoperative radiationResection rateSurgery patientsSurvival benefitSurvival impactImproved survivalEvaluation of the Association of Perioperative UGT1A1 Genotype–Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma
Catenacci D, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala M, Narula S, Alpert L, Setia N, Xiao S, Hart J, Siddiqui U, Peterson B, Moore K, Kipping-Johnson K, Markevicius U, Gordon B, Allen K, Racette C, Maron S, Liao C, Polite B, Kindler H, Turaga K, Prachand V, Roggin K, Ferguson M, Posner M. Evaluation of the Association of Perioperative UGT1A1 Genotype–Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma. JAMA Network Open 2020, 3: e1921290. PMID: 32058557, DOI: 10.1001/jamanetworkopen.2019.21290.Peer-Reviewed Original ResearchConceptsLocally advanced gastroesophageal adenocarcinomaPathological response gradeAdvanced gastroesophageal adenocarcinomaGastroesophageal adenocarcinomaResection rateMargin-negativeResponse gradeMargin-negative resection rateMedian disease-free survivalUGT1A1 genotype groupsMedian overall survivalLocally advanced adenocarcinomaHigher adverse eventsR0 resection rateDisease-free survivalCoprimary end pointsPhase 2 trialRate of recurrenceIntestinal-type tumorsR0 resectionR1 resectionAdvanced adenocarcinomaNeoadjuvant chemotherapyPerioperative therapyOverall survivalPhase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Chen E, Tormoen G, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G. Phase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma. Journal Of Clinical Oncology 2020, 38: 697-697. DOI: 10.1200/jco.2020.38.4_suppl.697.Peer-Reviewed Original ResearchGemcitabine/nab-paclitaxelPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaPre-operative therapyPre-operative treatmentNab-paclitaxelPancreatic resectionDuctal adenocarcinomaBorderline resectable pancreatic ductal adenocarcinomaSingle-arm phase II trialNab-paclitaxel chemotherapyPositive clinical nodesPhase II studyR0 resection ratePhase II trialNegative surgical marginsRelapse-free survivalMicro-metastatic diseaseIntensity-modulated radiation therapyGemcitabine 1000II trialPrimary endpointResection rateSecondary endpointsII study
2019
Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC).
Cohen D, Medina B, Du K, Coveler A, Manji G, Oberstein P, Perna S, Miller G. Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC). Journal Of Clinical Oncology 2019, 37: tps4163-tps4163. DOI: 10.1200/jco.2019.37.15_suppl.tps4163.Peer-Reviewed Original ResearchStereotactic body radiotherapyImmune suppressionResection rateUnacceptable toxicityEfficacy of SBRTPhase II multi-institutional studySingle-arm phase II studyAdvanced unresectable pancreatic cancerArm phase II studyHigher R0 resection rateAdaptive immune suppressionImmune suppressive phenotypeM-CSFPD-1 blockadePhase II studyR0 resection rateStandard induction chemotherapyUnresectable pancreatic cancerSurgical resection rateAnti-tumor responseT cell populationsEfficacy of RTPlacement of fiducialsPre-clinical modelsMulti-institutional study
2016
Colorectal endoscopic submucosal dissection: a systematic review and meta-analysis
Akintoye E, Kumar N, Aihara H, Nas H, Thompson C. Colorectal endoscopic submucosal dissection: a systematic review and meta-analysis. Endoscopy International Open 2016, 04: e1030-e1044. PMID: 27747275, PMCID: PMC5063641, DOI: 10.1055/s-0042-114774.Peer-Reviewed Original ResearchColorectal endoscopic submucosal dissectionEndoscopic submucosal dissectionR0 resectionResection rateAverage postoperative followR0 resection rateCurative resection rateFirst-line therapyAverage tumor sizeEn bloc resectionAdvanced endoscopic techniquesComprehensive literature searchMajor bleedingPostoperative followResection statusDelayed perforationClinical efficacyRecurrence rateSafety profileTumor sizeGastrointestinal tumorsTumor recurrenceSubmucosal dissectionColorectal tumorsEndoscopic techniquesIs long‐term survival possible after margin‐positive resection of retroperitoneal sarcoma (RPS)?
Klooster B, Rajeev R, Chrabaszcz S, Charlson J, Miura J, Bedi M, Gamblin T, Johnston F, Turaga K. Is long‐term survival possible after margin‐positive resection of retroperitoneal sarcoma (RPS)? Journal Of Surgical Oncology 2016, 113: 823-827. PMID: 27060344, DOI: 10.1002/jso.24232.Peer-Reviewed Original ResearchConceptsLong-term survivalMargin-positive resectionRetroperitoneal sarcomaR2 resectionResection of retroperitoneal sarcomaNational Cancer Database dataBenefit of chemotherapyCox regression modelsShort-term survivalCompare LTPositive resectionR0/R1 resectionMedian survivalResection rateImproved survivalPostoperative yearYounger patientsResectionFollow-upHistological characteristicsPatientsRegression modelsSurvivalChemotherapySarcomaEndoscopic submucosal dissection of gastric tumors: A systematic review and meta-analysis
Akintoye E, Obaitan I, Muthusamy A, Akanbi O, Olusunmade M, Levine D. Endoscopic submucosal dissection of gastric tumors: A systematic review and meta-analysis. World Journal Of Gastrointestinal Endoscopy 2016, 8: 517-532. PMID: 27606044, PMCID: PMC4980641, DOI: 10.4253/wjge.v8.i15.517.Peer-Reviewed Original ResearchGastric endoscopic submucosal dissectionEndoscopic submucosal dissectionR0 resectionResection rateSubmucosal dissectionGastric tumorsCurative resection rateFirst-line therapyR0 resection rateComprehensive literature searchMajor bleedingLine therapyResection statusClinical efficacyRecurrence rateSafety profileTumor recurrencePerforation rateStudy heterogeneitySystematic reviewMedical literatureLiterature searchTumorsWarrants considerationResection
2015
Racial disparities in the use of SBRT for treating early-stage lung cancer
Corso CD, Park HS, Kim AW, Yu JB, Husain Z, Decker RH. Racial disparities in the use of SBRT for treating early-stage lung cancer. Lung Cancer 2015, 89: 133-138. PMID: 26051446, DOI: 10.1016/j.lungcan.2015.05.002.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyUse of SBRTEarly-stage lung cancerBlack patientsExternal beam radiationWhite patientsAggressive therapyLung cancerRacial disparitiesNon-operative cohortNational Cancer DatabaseStage I NSCLCPrimary treatment modalitySurgical resection rateMultivariable logistic regressionPopulation-based studyPotential racial disparitiesInoperable candidatesSBRT useSBRT utilizationInoperable patientsResection rateSurgical resectionMultivariable analysisSurgical intervention
2010
Defining Venous Involvement in Borderline Resectable Pancreatic Cancer
Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, Astsaturov I, Hoffman JP. Defining Venous Involvement in Borderline Resectable Pancreatic Cancer. Annals Of Surgical Oncology 2010, 17: 2832-2838. PMID: 20725860, DOI: 10.1245/s10434-010-1284-9.Peer-Reviewed Original ResearchConceptsR0 resection ratePreoperative therapyPreoperative chemoradiationResection ratePancreatic adenocarcinomaVenous involvementBilateral narrowingUnilateral narrowingSurvival rateBorderline resectable pancreatic adenocarcinomaBorderline resectable pancreatic cancerMargin-negative resection rateMedian overall survival rateHigher R0 resection rateImproved overall survivalResectable pancreatic cancerNegative lymph nodesMargin-negative resectionOverall survival rateResectable pancreatic adenocarcinomaSuperior mesenteric veinPreoperative computed tomographyType IIBackgroundPancreatic adenocarcinomaBorderline resectability
2008
Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer
Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK. Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 37-45. PMID: 18166839, DOI: 10.1097/jto.0b013e31815e5d9a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCisplatinDeoxycytidineDrug Administration ScheduleFeasibility StudiesFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelSurvival AnalysisTime FactorsTreatment OutcomeConceptsEarly-stage non-small cell lung cancerNon-small cell lung cancerCell lung cancerGemcitabine 1000Day 1Neoadjuvant chemotherapyLung cancerResponse ratePathologic complete response rateRandomized phase II trialPhase III settingClinical response rateComplete response ratePerioperative mortality ratePrimary end pointComplete resection ratePhase II trialCarboplatin areaEligible patientsII trialPreoperative regimenResection rateSame regimenUnderwent surgeryMedian survival
2006
Neoadjuvant paclitaxel (P), carboplatin (Ca) and gemcitabine (G) in patients with locally advanced transitional cell carcinoma (TCC) of the bladder: A final report
Smith D, Mackler N, Hussain M, Dunn R, Montie J, Wood D, Lee C, Petrylak D, Quinn D, Vaishampayan U. Neoadjuvant paclitaxel (P), carboplatin (Ca) and gemcitabine (G) in patients with locally advanced transitional cell carcinoma (TCC) of the bladder: A final report. Journal Of Clinical Oncology 2006, 24: 4541-4541. DOI: 10.1200/jco.2006.24.18_suppl.4541.Peer-Reviewed Original ResearchTransitional cell carcinomaAdvanced transitional cell carcinomaPT0 rateArm IArm IITreatment of TCCGrade 3/4 hematologic toxicitiesM0 transitional cell carcinomaAdequate organ functionCycles of therapyGrade 3 toxicityPerformance status 0Pathologic complete respondersNational Cancer InstituteBristol-Myers SquibbNeoadjuvant paclitaxelStatus 0Complete respondersEvaluable subjectsHematologic toxicityNeoadjuvant chemotherapyPrimary endpointPositive patientsResection rateClinical T3
2005
Transhepatic Ipsilateral Right Portal Vein Embolization Extended to Segment IV: Improving Hypertrophy and Resection Outcomes with Spherical Particles and Coils
Madoff DC, Abdalla EK, Gupta S, Wu TT, Morris JS, Denys A, Wallace MJ, Morello FA, Ahrar K, Murthy R, Lunagomez S, Hicks ME, Vauthey JN. Transhepatic Ipsilateral Right Portal Vein Embolization Extended to Segment IV: Improving Hypertrophy and Resection Outcomes with Spherical Particles and Coils. Journal Of Vascular And Interventional Radiology 2005, 16: 215-225. PMID: 15713922, DOI: 10.1097/01.rvi.0000147067.79223.85.Peer-Reviewed Original ResearchMeSH KeywordsAcrylic ResinsAdultAgedBile Duct NeoplasmsCarcinoma, HepatocellularCause of DeathEmbolization, TherapeuticFemaleFollow-Up StudiesGelatinHepatectomyHumansHypertrophyLength of StayLiverLiver NeoplasmsMaleMicrospheresMiddle AgedPolyvinyl AlcoholPortal VeinRetrospective StudiesSafetyTomography, Spiral ComputedTreatment OutcomeConceptsTotal estimated liver volumeRight portal vein embolizationTris-acryl microspheresRight PVEPortal vein embolizationRight hepatectomyFLR volumeResection rateVein embolizationLiver volumeEstimated liver volumeMalignant hepatobiliary diseaseProgressive liver insufficiencyMedian hospital stayPercent of patientsExtended right hepatectomyResult of sepsisFuture liver remnantPostembolization syndromeTomographic volumetryHospital stayFLR hypertrophyPostoperative outcomesResection outcomesBiliary cancer
2002
Aberrant p53 Staining Does Not Predict Cisplatin Resistance in Locally Advanced Non-Small Cell Lung Cancer
Johnson E, Klimstra D, Herndon J, Catalano E, Canellos G, Graziano S, Kern J, Green M. Aberrant p53 Staining Does Not Predict Cisplatin Resistance in Locally Advanced Non-Small Cell Lung Cancer. Cancer Investigation 2002, 20: 686-692. PMID: 12197224, DOI: 10.1081/cnv-120003537.Peer-Reviewed Original ResearchConceptsCell lung cancerP53 stainingResistance to cisplatinLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerLung cancerMediastinal lymph node specimensNon-small cell lung cancerLeukemia Group B protocolsNonsmall cell lung cancerTumor resistance to cisplatinPartial resection ratePositive p53 stainingPost-operative chemotherapyResponse to chemotherapyAberrant p53 stainingGroup B protocolMutation of p53Lymph node specimensResistance in vitroPlatinum regimensMedian survivalStage IIIAResection rateStaging mediastinoscopy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply